NCT06518564 - Avelumab and M1774 in ARID1A-mutated Endometrial Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 14, 2024

Primary Completion Date

August 31, 2027

Study Completion Date

August 31, 2029

Conditions

Endometrial CancerARID1A Gene MutationRecurrent Endometrial Carcinoma

Interventions

DRUG

Avelumab

Human IgG1 antibody, 20mL single-use vials, via intravenous (into the vein) infusion per protocol.

DRUG

M1774

Ataxia Telangiectasia and Rad3-related protein (ATR) inhibitor, 30 and 50 mg capsules, taken orally per protocol.

Trial Locations (2)

RECRUITING

Dana-Farber Cancer Institute, Boston

RECRUITING

Brigham and Women's Hospital, Boston